Is Miaoshou Doctor profitable in 2026?

No. Miaoshou Doctor's operator, Beijing Yuanxin Technology Group, reported a net loss of RMB757 million in 2021, nearly four times its RMB201 million loss in 2019, with adjusted losses growing from RMB172 million to RMB622 million over the same period. No later HKEX filing shows a return to profit.

Is Miaoshou Doctor going public in 2026?

It filed for a sixth Hong Kong IPO attempt around May 2026, targeting roughly RMB19.5 billion (about $2.7 billion), down from its earlier $4.25 billion unicorn valuation. The company has failed five prior HK listing attempts since 2021, so completion is unconfirmed.

Who owns Miaoshou Doctor?

Miaoshou Doctor is the consumer app of Beijing Yuanxin Technology Group, a private, venture-backed Chinese health company. Investors include Sequoia China (HongShan) and Tencent, who co-led a $465 million Series E in February 2021, plus Qiming Venture Partners and OrbiMed.

Could AI replace Miaoshou Doctor's consultation business?

It's exposed. Rival JD Health launched AI Jingyi, Dr. Da Wei, and Zhiyi between 2025 and early 2026 to automate consultation and triage, while no comparable named AI product from Miaoshou Doctor has surfaced as of March 2026, leaving its core consult layer vulnerable to commoditization.

Who is Miaoshou Doctor's biggest competitor?

JD Health is the market leader in China's online healthcare space, drawing about 83% of revenue from online pharmacy as of March 2026, and is far larger and better capitalized than Miaoshou Doctor. Alibaba Health and Ping An Good Doctor also outscale it.

What is Miaoshou Doctor's current valuation?

Its May 2026 sixth Hong Kong IPO filing targets a listing valuation of about RMB19.5 billion, roughly $2.7 billion, down from a historic private peak unicorn valuation of about $4.25 billion, an approximately 35% markdown.

China · China

Miaoshou Doctor

Chinese online platform linking telehealth consults, internet hospital, and pharmacy delivery.

Little protection left

Assessed 29 July 2026 · Evidence as of 29 July 2026

Not much stands between this business and its pressures.

On the recordSince 29 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: Sixth Hong Kong IPO filing outcome, targeting roughly $2.7B valuation

The call

Miaoshou Doctor keeps filing for a Hong Kong listing while bigger rivals ship AI tools into the same consult-and-pharmacy business it built.

Miaoshou Doctor lets patients talk to doctors online, get prescriptions filled, and have medicine delivered to their door. Bigger companies like JD Health and Alibaba Health already do the same thing and have way more money, so they can copy every part of Miaoshou's playbook easily. What makes this harder: JD Health and others are now rolling out AI tools that can answer basic health questions and suggest medicines without a human doctor, which threatens to shrink the very reason people pay for Miaoshou's service. The one thing that could change the picture: if Miaoshou launches its own standout AI product that works as well as JD Health's new systems, or if it commits to serving one specific group of patients (like people with chronic diseases who use its pharmacies regularly) that the giants have not yet locked down.

Why

AI pressure: JD Health's AI Jingyi, Dr. Da Wei, and Zhiyi tools. JD Health already runs AI triage and consult bots across the same online-consult-to-pharmacy path Miaoshou sells. Could AI do the core job? Yes, likely.

Bigger players: JD Health, Alibaba Health, Ping An Good Doctor. All three run larger online pharmacy and consult platforms covering the same city markets Miaoshou serves. Could a giant copy it? Yes, easily.

What protects it. 264 physical Yuanxin pharmacies, ties to 200+ hospitals, and an internet hospital license from 2017.

What would change this call

Outcome of Miaoshou Doctor's sixth Hong Kong IPO filing due around May 2026. Shows whether capital markets still trust its scale and growth story.
Whether Miaoshou Doctor ships a named AI product comparable to JD Health's AI Jingyi or Zhiyi. Shows if it can match rivals' AI-driven consult and pharmacy automation.
Q2 to Q3 2026 financial results showing net loss trend versus RMB757M 2021 loss. Shows whether losses are narrowing or still growing against bigger rivals.

Key numbers

Net loss hit RMB757M in 2021, up from RMB201M in 2019 (2021-12-31)
Private valuation cut from $4.25B peak to ~$2.7B IPO target (2026-05-07)
40M+ monthly active users, 1.3M registered doctors on platform (2026-05-15)

Named risks

Six failed Hong Kong IPO attempts since 2021 with valuation markdown to ~$2.7B. Severity: high
No shipped named AI product versus JD Health's 2025-2026 AI launches. Severity: high
Persistent widening losses, net loss nearly quadrupling 2019 to 2021. Severity: high
China internet-hospital licensing and prescription e-commerce rules could shift. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
JD Health	losing to	JD Health shipped AI Jingyi, Dr. Da Wei, Zhiyi 2025-2026; Miaoshou has no named AI product as of 2026-03
Alibaba Health	losing to	Larger e-commerce and cloud-backed rival expanding AI-assisted healthcare as of 2026-03
Ping An Good Doctor	losing to	192.8M+ registered users and ~$15B+ market cap vs Miaoshou's 40M MAU, per 2025-07 data
Meituan	contesting	Entered on-demand drug delivery, pressuring incumbents on speed as of 2026-03

Questions people ask

Is Miaoshou Doctor profitable in 2026?: No. Miaoshou Doctor's operator, Beijing Yuanxin Technology Group, reported a net loss of RMB757 million in 2021, nearly four times its RMB201 million loss in 2019, with adjusted losses growing from RMB172 million to RMB622 million over the same period. No later HKEX filing shows a return to profit.
Is Miaoshou Doctor going public in 2026?: It filed for a sixth Hong Kong IPO attempt around May 2026, targeting roughly RMB19.5 billion (about $2.7 billion), down from its earlier $4.25 billion unicorn valuation. The company has failed five prior HK listing attempts since 2021, so completion is unconfirmed.
Who owns Miaoshou Doctor?: Miaoshou Doctor is the consumer app of Beijing Yuanxin Technology Group, a private, venture-backed Chinese health company. Investors include Sequoia China (HongShan) and Tencent, who co-led a $465 million Series E in February 2021, plus Qiming Venture Partners and OrbiMed.
Could AI replace Miaoshou Doctor's consultation business?: It's exposed. Rival JD Health launched AI Jingyi, Dr. Da Wei, and Zhiyi between 2025 and early 2026 to automate consultation and triage, while no comparable named AI product from Miaoshou Doctor has surfaced as of March 2026, leaving its core consult layer vulnerable to commoditization.
Who is Miaoshou Doctor's biggest competitor?: JD Health is the market leader in China's online healthcare space, drawing about 83% of revenue from online pharmacy as of March 2026, and is far larger and better capitalized than Miaoshou Doctor. Alibaba Health and Ping An Good Doctor also outscale it.
What is Miaoshou Doctor's current valuation?: Its May 2026 sixth Hong Kong IPO filing targets a listing valuation of about RMB19.5 billion, roughly $2.7 billion, down from a historic private peak unicorn valuation of about $4.25 billion, an approximately 35% markdown.

Timeline

2026-05-07Files sixth Hong Kong IPO attempt targeting roughly $2.7B valuation
2026-03-12JD Health reported shipping AI Jingyi, Dr. Da Wei, and Zhiyi AI tools
2025-07-11Company profile cites 1,200+ hospital and clinic partnerships
2022-04-27HK IPO filing discloses RMB757M net loss for 2021
2021-02-21Raises $465M Series E led by Sequoia China and Tencent
2019-07-13Closes $72.8M Series C+ round above $1B valuation
2017Obtains internet hospital license
2015Miaoshou Doctor app launched; company founded

Revision history

29 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

JOLLY Information Technology DeepBlue Technology 56PINGTAI